Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term FOLLOW-UP. Found 14 abstracts

Chang BL, Hughes L, Chen DY, Gross L, Ruth K, Giri VN. Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer. BJU international. 2014 May;113(5B):E150-E156.   PMCID: PMC 3830710
Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP. Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Journal of Clinical Oncology. 2014 May;32(15):1563-70.   PMCID: PMC 4026579
Kim SP, Karnes RJ, Nguyen PL, Ziegenfuss JY, Thompson RH, Han LC, Shah ND, Smaldone MC, Gross CP, Frank I, Weight CJ, Beebe TJ, Tilburt JC. A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer. BJU international. 2014 May;113(5B):E106-E111.
Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White M, Artioli G, Dudlicek L, Olopade OL. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genetics in Medicine. 2008 Mar;10(3):161-6.
Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. Journal of Clinical Oncology. 2008 Mar;26(8):1331-7.
Wahl AO, Rademaker A, Kiel KD, Jones EL, Marks LB, Croog V, McCormick BM, Hirsch A, Karkar A, Motwani SB, Tereffe W, Yu TK, Sher D, Silverstein J, Kachnic LA, Kesslering C, Freedman GM, Small W. Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer. International Journal of Radiation Oncology Biology Physics. 2008 Feb;70(2):477-84.
Coyne JC, Pajak TF, Harris J, Konski A, Movsas B, Ang K, Bruner DW. Emotional well-being does not predict survival in head and neck cancer patients - A radiation therapy oncology group study. Cancer. 2007 Dec;110(11):2568-75.
Egleston BL, Scharfstein DO, Freeman EE, West SK. Causal inference for non-mortality outcomes in the presence of death. Biostatistics. 2007 Jul;8(3):526-45.
Emmanouilides C, Witzig TE, Wiseman GA, Gordon LI, Wang H, Schilder R, Saville MW, Flinn I, Molina A. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-hodgkin's lymphoma. Cancer Biotherapy and Radiopharmaceuticals. 2007 Oct;22(5):684-91.
Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A. Radiation dose and late failures in prostate cancer. International Journal of Radiation Oncology Biology Physics. 2007 Mar;67(4):1074-81.
Wiseman GA, Conti PS, Vo K, Schilder RJ, Gordon LI, Emmanouilides C, Silverman DH, Witzig TE, Darif M, Molina A. Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Clinical Lymphoma & Myeloma. 2007 Sep;7(8):514-7.
Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, Darif M, Macklis R, Vo K, Wiseman GA. Long-term responses in patients with recurring or refractory B-Ccll non-hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007 May;109(9):1804-10.
Jimbo M, Meyer B, Hyslop T, Cocroft J, Turner BJ, Weinberg DS, Myers RE. Effectiveness of complete diagnostic examination in clinical practice settings. Cancer Detection and Prevention. 2006 Jan;30(6):545-51.
Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer. 2004 Feb;100(3):538-43.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term FOLLOW-UP

FOLLOW-UP LOW-GRADE THERAPY screening PHASE-II FOLLICULAR LYMPHOMA RADIOIMMUNOTHERAPY radioimmunotherapy prostate-specific antigen TRIAL PROGNOSTIC-FACTORS EXTERNAL-BEAM RADIATION BIOCHEMICAL FAILURE OVARIAN-CANCER SURGERY Urology & Nephrology REDUCTION MORTALITY prostate cancer RECURRENCE radiotherapy WOMEN CONFORMAL RADIOTHERAPY HORMONE REPLACEMENT THERAPY HIV VACCINE TRIALS BRAF MUTATIONS breast cancer abnormal findings HEALTH GUIDELINE TYROSINE KINASE ASSOCIATION radiopharmaceuticals MALIGNANT-MELANOMA IMATINIB MESYLATE genetics SUSCEPTIBILITY BREAST-CANCER RISK VIRAL LOAD VISUAL IMPAIRMENT analysis RADICAL PROSTATECTOMY CONSERVING SERVICES TASK-FORCE sensitivity ELDERLY PEOPLE BRCA2 BRCA2 MUTATION CARRIERS biochemical failure QUALITY-OF-LIFE prophylactic salpingo-oophorectomy survival vision loss RISK PATIENTS RADIATION-THERAPY ANTIGEN MEN I-131 TOSITUMOMAB CELL LYMPHOMA MILD THROMBOCYTOPENIA SDHA indium 111 ibritumomab tiuxetan prostate carcinoma GENOME-WIDE ASSOCIATION COLORECTAL-CANCER prostatic neoplasms DISEASE KeyWords Plus: HYPERTHERMIA POPULATION CONFORMAL RADIATION-THERAPY follow-up studies SURVEILLANCE depression cancer fecal occult blood test distant metastasis outcomes cancer screening CHEMOTHERAPY PSYCHOLOGICAL RESPONSE FAMILY-HISTORY B-CELL LYMPHOMA DISTANT METASTASIS ELDERLY-PATIENTS psychosocial mass complete diagnostic radiation dose BRCA1 family history STRATIFICATION non-Hodgkin lymphoma (NHL) survey THROMBOCYTOPENIA diagnosis INHERITED MUTATIONS PRINCIPAL occult blood radioimmunoconjugates PSA ERA ANTI-CD20 MONOCLONAL-ANTIBODY OLDER-ADULTS Oncology colorectal neoplasm RANDOMIZED TRIAL R-CHOP competing risk FECAL-OCCULT-BLOOD BILATERAL PROPHYLACTIC OOPHORECTOMY IODINE I-131 TOSITUMOMAB SURVIVAL ADVANTAGE SURVIVAL PENETRANCE TAMOXIFEN Y-90 ibritumomab metastasis SOCIETY ibritumomab tiuxetan radioimmunotherapy-non-Hodgkin's lymphoma-elderly repeat irradiation toxicity MANAGEMENT OUTCOMES METASTATIC BREAST-CANCER RANDOMIZED-TRIAL METASTATIC DISSEMINATION IRRADIATION TUMOR emotional distress MILD mortality DEPRESSIVE SYMPTOMS CONSERVATION THERAPY tiuxetan well-being emotional PSYCHOSOCIAL FACTORS LOCI LOCAL-CONTROL BONE-MARROW-TRANSPLANTATION RECEPTOR head and neck causal inference LOCAL-REGIONAL RECURRENCE evaluation ESTROGEN-RECEPTOR STATUS hazard function INTERNATIONAL PROGNOSTIC INDEX hyperthermia time to progression (TTP)
Last updated on Wednesday, July 08, 2020